NAC pharmacy order.
Ended Awarded Last action
- Contract number
- 36C26024F0449
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $777,681
Award facts
- Contract value 100% obligated
- $777,681.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $19,850 | |
| Other Administrative Action | -$19,850 | |
| Supplemental Agreement for work within scope | $180,436 | |
| Supplemental Agreement for work within scope | $200,286 | |
| Original award | $396,959 |
About this award
Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $777,681.26 for pharmacy supplies under a firm fixed-price contract with the Department of Veterans Affairs' Veterans Integrated Service Network 20. The award, issued on July 1, 2024, with an ultimate completion date of June 30, 2025, represents a child contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). This delivery order is not set aside and will be performed at the contractor's facility in North Billerica, Massachusetts. Progenics Pharmaceuticals specializes in providing PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography scans for prostate cancer detection and imaging across federal healthcare providers.
This award reflects the ongoing demand for specialized radiopharmaceuticals within the Veterans Health Administration's medical imaging programs. Progenics Pharmaceuticals, as a subsidiary of Lantheus Holdings, maintains significant indefinite delivery vehicles with the VA and Defense Health Agency, including a $290 million Federal Supply Schedule contract running through March 2030. The company's federal contracting portfolio demonstrates consistent engagement in supplying critical nuclear medicine and diagnostic imaging products to military treatment facilities and Veterans Affairs medical centers nationwide. The firm fixed-price structure and delivery order format enable efficient procurement of these essential medical imaging agents for veteran healthcare services.
Quick answers
Who was awarded contract 36C26024F0449?
36C26024F0449 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on July 1, 2024.
How much is contract 36C26024F0449 worth?
The government has obligated $777,681 on 36C26024F0449.
Is contract 36C26024F0449 an order under another contract?
Yes. 36C26024F0449 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26024F0449 competed?
The extent of competition for 36C26024F0449 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award